vivoPharm expands, TGR contracts
Wednesday, 06 February, 2008
Adelaide-based contract research organisation vivoPharm is to open a European subsidiary in Germany after receiving an injection of venture capital funds.
vivoPharm Europe will be based in Munich and headed by Dr Katja Wosikowski. It aims to develop new business and maintain relationships with existing customers in Austria, Germany, Switzerland, Spain and Norway.
vivoPharm was established in 2003 and offers integrated preclinical services to the biotechnology and pharmaceutical industries.
It received $1 million in venture capital from the South Australian Life Sciences Advancement Fund, managed by Terra Rossa Capital.
Another Adelaide biotech, TGR BioSciences, has appointed former PricewaterhouseCoopers (PwC) life sciences specialist Andrew Sneddon to its board.
TGR specialises in drug discovery for oral and gastrointestinal health and skin and tissue repair.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
